Crossmark

Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma

Crossref DOI link: https://doi.org/10.1038/srep36060

Published Online: 2016-11-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wen, Feng

Zheng, Hanrui

Wu, Yifan

Wheeler, John

Zeng, Xiaoxi

Fu, Ping

Li, Qiu
License Information

Text and Data Mining valid from 2016-11-08

Version of Record valid from 2016-11-08
More Information

Article History

Received: 13 April 2016

Accepted: 10 October 2016

First Online: 8 November 2016

Competing interests

: The authors declare no competing financial interests.

Document is current

Any future updates will be listed below